Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NuVasive, Medtronic settle litigation

This article was originally published in The Gray Sheet

Executive Summary

Firms resolve all legal action related to Medtronic's assertion that NuVasive interfered with non-competition and confidentiality agreements by hiring three former Sofamor Danek employees, a Nov. 15 release says. All outstanding lawsuits have been dismissed with prejudice and the parties are keeping the terms of the resolution confidential, according to NuVasive. Medtronic first sued the San Diego firm in 2001 (1"The Gray Sheet" March 15, 2004, p. 22). NuVasive, which plans to enter the artificial disc market with its Maximum Access Surgery system, recently completed an IPO to raise funds to develop injectable disc nucleus replacement materials and total lumbar disc products...

You may also be interested in...



NuVasive IPO: Minimally Invasive Spine Firm Offers Up To $92 Mil. In Stock

NuVasive plans to use proceeds from its initial public offering to develop injectable disc nucleus replacement materials and total lumbar disc products

Chloroquine ‘Approval’ For COVID-19 And The US FDA’s New Reality

Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.

Biopharma, Payers Seek National Guidelines For Prescribing Potential COVID-19 Drugs

Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.

UsernamePublicRestriction

Register

MT021216

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel